Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
37
BIS Quote, Financials, Valuation and Earnings
Last price:
$9.04
Seasonality move
:
-2.35%
Day range:
$8.99 - $9.04
52-week range:
$9.14 - $25.87
Dividend yield:
6.65%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2.8K
Avg. volume:
19.5K
1-year change:
-49.1%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BIS
ProShares UltraShort Nasdaq Biotechnology
|
-- | -- | -- | -- | -- |
|
FXP
ProShares UltraShort FTSE China 50
|
-- | -- | -- | -- | -- |
|
PSQ
ProShares Short QQQ
|
-- | -- | -- | -- | -- |
|
QID
ProShares UltraShort QQQ
|
-- | -- | -- | -- | -- |
|
SKYU
ProShares Ultra Nasdaq Cloud Computing
|
-- | -- | -- | -- | -- |
|
SQQQ
ProShares UltraPro Short QQQ
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BIS
ProShares UltraShort Nasdaq Biotechnology
|
$9.04 | -- | -- | -- | $0.10 | 6.65% | -- |
|
FXP
ProShares UltraShort FTSE China 50
|
$18.05 | -- | -- | -- | $0.18 | 9.71% | -- |
|
PSQ
ProShares Short QQQ
|
$30.17 | -- | -- | -- | $0.36 | 5.97% | -- |
|
QID
ProShares UltraShort QQQ
|
$20.02 | -- | -- | -- | $0.25 | 7.02% | -- |
|
SKYU
ProShares Ultra Nasdaq Cloud Computing
|
$38.20 | -- | -- | -- | $0.08 | 0.33% | -- |
|
SQQQ
ProShares UltraPro Short QQQ
|
$67.24 | -- | -- | -- | $1.21 | 13.37% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BIS
ProShares UltraShort Nasdaq Biotechnology
|
-- | -1.801 | -- | -- |
|
FXP
ProShares UltraShort FTSE China 50
|
-- | -0.284 | -- | -- |
|
PSQ
ProShares Short QQQ
|
-- | -1.365 | -- | -- |
|
QID
ProShares UltraShort QQQ
|
-- | -2.677 | -- | -- |
|
SKYU
ProShares Ultra Nasdaq Cloud Computing
|
-- | 3.848 | -- | -- |
|
SQQQ
ProShares UltraPro Short QQQ
|
-- | -3.889 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BIS
ProShares UltraShort Nasdaq Biotechnology
|
-- | -- | -- | -- | -- | -- |
|
FXP
ProShares UltraShort FTSE China 50
|
-- | -- | -- | -- | -- | -- |
|
PSQ
ProShares Short QQQ
|
-- | -- | -- | -- | -- | -- |
|
QID
ProShares UltraShort QQQ
|
-- | -- | -- | -- | -- | -- |
|
SKYU
ProShares Ultra Nasdaq Cloud Computing
|
-- | -- | -- | -- | -- | -- |
|
SQQQ
ProShares UltraPro Short QQQ
|
-- | -- | -- | -- | -- | -- |
ProShares UltraShort Nasdaq Biotechnology vs. Competitors
-
Which has Higher Returns BIS or FXP?
ProShares UltraShort FTSE China 50 has a net margin of -- compared to ProShares UltraShort Nasdaq Biotechnology's net margin of --. ProShares UltraShort Nasdaq Biotechnology's return on equity of -- beat ProShares UltraShort FTSE China 50's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BISProShares UltraShort Nasdaq Biotechnology-- -- -- FXPProShares UltraShort FTSE China 50-- -- -- -
What do Analysts Say About BIS or FXP?
ProShares UltraShort Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares UltraShort FTSE China 50 has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares UltraShort Nasdaq Biotechnology has higher upside potential than ProShares UltraShort FTSE China 50, analysts believe ProShares UltraShort Nasdaq Biotechnology is more attractive than ProShares UltraShort FTSE China 50.
Company Buy Ratings Hold Ratings Sell Ratings BISProShares UltraShort Nasdaq Biotechnology0 0 0 FXPProShares UltraShort FTSE China 500 0 0 -
Is BIS or FXP More Risky?
ProShares UltraShort Nasdaq Biotechnology has a beta of -1.422, which suggesting that the stock is 242.163% less volatile than S&P 500. In comparison ProShares UltraShort FTSE China 50 has a beta of -0.929, suggesting its less volatile than the S&P 500 by 192.906%.
-
Which is a Better Dividend Stock BIS or FXP?
ProShares UltraShort Nasdaq Biotechnology has a quarterly dividend of $0.10 per share corresponding to a yield of 6.65%. ProShares UltraShort FTSE China 50 offers a yield of 9.71% to investors and pays a quarterly dividend of $0.18 per share. ProShares UltraShort Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares UltraShort FTSE China 50 pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIS or FXP?
ProShares UltraShort Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares UltraShort FTSE China 50 quarterly revenues of --. ProShares UltraShort Nasdaq Biotechnology's net income of -- is lower than ProShares UltraShort FTSE China 50's net income of --. Notably, ProShares UltraShort Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares UltraShort FTSE China 50's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares UltraShort Nasdaq Biotechnology is -- versus -- for ProShares UltraShort FTSE China 50. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BISProShares UltraShort Nasdaq Biotechnology-- -- -- -- FXPProShares UltraShort FTSE China 50-- -- -- --
-
Which has Higher Returns BIS or PSQ?
ProShares Short QQQ has a net margin of -- compared to ProShares UltraShort Nasdaq Biotechnology's net margin of --. ProShares UltraShort Nasdaq Biotechnology's return on equity of -- beat ProShares Short QQQ's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BISProShares UltraShort Nasdaq Biotechnology-- -- -- PSQProShares Short QQQ-- -- -- -
What do Analysts Say About BIS or PSQ?
ProShares UltraShort Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares Short QQQ has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares UltraShort Nasdaq Biotechnology has higher upside potential than ProShares Short QQQ, analysts believe ProShares UltraShort Nasdaq Biotechnology is more attractive than ProShares Short QQQ.
Company Buy Ratings Hold Ratings Sell Ratings BISProShares UltraShort Nasdaq Biotechnology0 0 0 PSQProShares Short QQQ0 0 0 -
Is BIS or PSQ More Risky?
ProShares UltraShort Nasdaq Biotechnology has a beta of -1.422, which suggesting that the stock is 242.163% less volatile than S&P 500. In comparison ProShares Short QQQ has a beta of -1.194, suggesting its less volatile than the S&P 500 by 219.382%.
-
Which is a Better Dividend Stock BIS or PSQ?
ProShares UltraShort Nasdaq Biotechnology has a quarterly dividend of $0.10 per share corresponding to a yield of 6.65%. ProShares Short QQQ offers a yield of 5.97% to investors and pays a quarterly dividend of $0.36 per share. ProShares UltraShort Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares Short QQQ pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIS or PSQ?
ProShares UltraShort Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares Short QQQ quarterly revenues of --. ProShares UltraShort Nasdaq Biotechnology's net income of -- is lower than ProShares Short QQQ's net income of --. Notably, ProShares UltraShort Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares Short QQQ's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares UltraShort Nasdaq Biotechnology is -- versus -- for ProShares Short QQQ. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BISProShares UltraShort Nasdaq Biotechnology-- -- -- -- PSQProShares Short QQQ-- -- -- --
-
Which has Higher Returns BIS or QID?
ProShares UltraShort QQQ has a net margin of -- compared to ProShares UltraShort Nasdaq Biotechnology's net margin of --. ProShares UltraShort Nasdaq Biotechnology's return on equity of -- beat ProShares UltraShort QQQ's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BISProShares UltraShort Nasdaq Biotechnology-- -- -- QIDProShares UltraShort QQQ-- -- -- -
What do Analysts Say About BIS or QID?
ProShares UltraShort Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares UltraShort QQQ has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares UltraShort Nasdaq Biotechnology has higher upside potential than ProShares UltraShort QQQ, analysts believe ProShares UltraShort Nasdaq Biotechnology is more attractive than ProShares UltraShort QQQ.
Company Buy Ratings Hold Ratings Sell Ratings BISProShares UltraShort Nasdaq Biotechnology0 0 0 QIDProShares UltraShort QQQ0 0 0 -
Is BIS or QID More Risky?
ProShares UltraShort Nasdaq Biotechnology has a beta of -1.422, which suggesting that the stock is 242.163% less volatile than S&P 500. In comparison ProShares UltraShort QQQ has a beta of -2.386, suggesting its less volatile than the S&P 500 by 338.587%.
-
Which is a Better Dividend Stock BIS or QID?
ProShares UltraShort Nasdaq Biotechnology has a quarterly dividend of $0.10 per share corresponding to a yield of 6.65%. ProShares UltraShort QQQ offers a yield of 7.02% to investors and pays a quarterly dividend of $0.25 per share. ProShares UltraShort Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares UltraShort QQQ pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIS or QID?
ProShares UltraShort Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares UltraShort QQQ quarterly revenues of --. ProShares UltraShort Nasdaq Biotechnology's net income of -- is lower than ProShares UltraShort QQQ's net income of --. Notably, ProShares UltraShort Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares UltraShort QQQ's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares UltraShort Nasdaq Biotechnology is -- versus -- for ProShares UltraShort QQQ. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BISProShares UltraShort Nasdaq Biotechnology-- -- -- -- QIDProShares UltraShort QQQ-- -- -- --
-
Which has Higher Returns BIS or SKYU?
ProShares Ultra Nasdaq Cloud Computing has a net margin of -- compared to ProShares UltraShort Nasdaq Biotechnology's net margin of --. ProShares UltraShort Nasdaq Biotechnology's return on equity of -- beat ProShares Ultra Nasdaq Cloud Computing's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BISProShares UltraShort Nasdaq Biotechnology-- -- -- SKYUProShares Ultra Nasdaq Cloud Computing-- -- -- -
What do Analysts Say About BIS or SKYU?
ProShares UltraShort Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares Ultra Nasdaq Cloud Computing has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares UltraShort Nasdaq Biotechnology has higher upside potential than ProShares Ultra Nasdaq Cloud Computing, analysts believe ProShares UltraShort Nasdaq Biotechnology is more attractive than ProShares Ultra Nasdaq Cloud Computing.
Company Buy Ratings Hold Ratings Sell Ratings BISProShares UltraShort Nasdaq Biotechnology0 0 0 SKYUProShares Ultra Nasdaq Cloud Computing0 0 0 -
Is BIS or SKYU More Risky?
ProShares UltraShort Nasdaq Biotechnology has a beta of -1.422, which suggesting that the stock is 242.163% less volatile than S&P 500. In comparison ProShares Ultra Nasdaq Cloud Computing has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BIS or SKYU?
ProShares UltraShort Nasdaq Biotechnology has a quarterly dividend of $0.10 per share corresponding to a yield of 6.65%. ProShares Ultra Nasdaq Cloud Computing offers a yield of 0.33% to investors and pays a quarterly dividend of $0.08 per share. ProShares UltraShort Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares Ultra Nasdaq Cloud Computing pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIS or SKYU?
ProShares UltraShort Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares Ultra Nasdaq Cloud Computing quarterly revenues of --. ProShares UltraShort Nasdaq Biotechnology's net income of -- is lower than ProShares Ultra Nasdaq Cloud Computing's net income of --. Notably, ProShares UltraShort Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares Ultra Nasdaq Cloud Computing's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares UltraShort Nasdaq Biotechnology is -- versus -- for ProShares Ultra Nasdaq Cloud Computing. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BISProShares UltraShort Nasdaq Biotechnology-- -- -- -- SKYUProShares Ultra Nasdaq Cloud Computing-- -- -- --
-
Which has Higher Returns BIS or SQQQ?
ProShares UltraPro Short QQQ has a net margin of -- compared to ProShares UltraShort Nasdaq Biotechnology's net margin of --. ProShares UltraShort Nasdaq Biotechnology's return on equity of -- beat ProShares UltraPro Short QQQ's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BISProShares UltraShort Nasdaq Biotechnology-- -- -- SQQQProShares UltraPro Short QQQ-- -- -- -
What do Analysts Say About BIS or SQQQ?
ProShares UltraShort Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares UltraPro Short QQQ has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares UltraShort Nasdaq Biotechnology has higher upside potential than ProShares UltraPro Short QQQ, analysts believe ProShares UltraShort Nasdaq Biotechnology is more attractive than ProShares UltraPro Short QQQ.
Company Buy Ratings Hold Ratings Sell Ratings BISProShares UltraShort Nasdaq Biotechnology0 0 0 SQQQProShares UltraPro Short QQQ0 0 0 -
Is BIS or SQQQ More Risky?
ProShares UltraShort Nasdaq Biotechnology has a beta of -1.422, which suggesting that the stock is 242.163% less volatile than S&P 500. In comparison ProShares UltraPro Short QQQ has a beta of -3.551, suggesting its less volatile than the S&P 500 by 455.061%.
-
Which is a Better Dividend Stock BIS or SQQQ?
ProShares UltraShort Nasdaq Biotechnology has a quarterly dividend of $0.10 per share corresponding to a yield of 6.65%. ProShares UltraPro Short QQQ offers a yield of 13.37% to investors and pays a quarterly dividend of $1.21 per share. ProShares UltraShort Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares UltraPro Short QQQ pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIS or SQQQ?
ProShares UltraShort Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares UltraPro Short QQQ quarterly revenues of --. ProShares UltraShort Nasdaq Biotechnology's net income of -- is lower than ProShares UltraPro Short QQQ's net income of --. Notably, ProShares UltraShort Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares UltraPro Short QQQ's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares UltraShort Nasdaq Biotechnology is -- versus -- for ProShares UltraPro Short QQQ. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BISProShares UltraShort Nasdaq Biotechnology-- -- -- -- SQQQProShares UltraPro Short QQQ-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
